Edition: BP 2025 (Ph. Eur. 11.6 update)
General Notices
Prolonged-release Ibuprofen Tablets
Ibuprofen Prolonged-release Tablets from different manufacturers, whilst complying with the requirements of the monograph, are not interchangeable unless otherwise justified and authorised..
Action and use
Cyclo-oxygenase inhibitor; analgesic; anti-inflammatory.
DEFINITION
Ibuprofen Prolonged-release Tablets contain Ibuprofen. They are formulated so that the medicament is released over a period of several hours.
PRODUCTION
A suitable dissolution test is carried out to demonstrate the appropriate release of Ibuprofen. The dissolution profile reflects the in vivo performance which in turn is compatible with the dosage schedule recommended by the manufacturer.
The tablets comply with the requirements stated under Tablets and with the following requirements.
Content of ibuprofen, C13H18O2
95.0 to 105.0% of the stated amount.
IDENTIFICATION
Extract a quantity of the powdered tablets containing 0.5 g of Ibuprofen with 20 mL of acetone, filter and evaporate the filtrate to dryness in a current of air without heating. The infrared absorption spectrum of the residue, Appendix II A, is concordant with the reference spectrum of ibuprofen (RS 186).
TESTS
Related substances
Carry out the method for liquid chromatography, Appendix III D, using the following solutions.
(1) Disperse a quantity of the powdered tablets containing 0.2 g of Ibuprofen with 20 mL of acetonitrile R1 and add sufficient mobile phase A to produce 100 mL.
(2) Dilute 1 volume of solution (1) to 100 volumes with mobile phase A. Further dilute 1 volume to 10 volumes with mobile phase A.
(3) Dissolve 20 mg of ibuprofen BPCRS in 2 mL of acetonitrile R1, add 1 mL of a 0.006% w/v solution of ibuprofen impurity B BPCRS in acetonitrile R1 and dilute to 10 mL with mobile phase A.
(4) 0.0006% w/v of 4′-isobutylacetophenone BPCRS (impurity E) in mobile phase A.
(5) Dissolve the contents of a vial of ibuprofen for peak identification EPCRS in 1 mL of acetonitrile R1 and dilute to 5 mL with mobile phase A.
CHROMATOGRAPHIC CONDITIONS
(a) Use a stainless steel column (15 cm × 4.6 mm) packed with end-capped octadecylsilyl amorphous organosilica polymer for chromatography (5 μm) (XTerra MS C18 is suitable).
(b) Use gradient elution and the mobile phase described below.
(c) Use a flow rate of 2 mL per minute.
(d) Use an ambient column temperature.
(e) Use a detection wavelength of 214 nm.
(f) Inject 20 μL of each solution.
MOBILE PHASE
Mobile phase A 0.5 volume of orthophosphoric acid, 340 volumes of acetonitrile R1 and sufficient water to produce 1000 volumes.
Mobile phase B 0.5 volume of orthophosphoric acid, 100 volumes of water and sufficient acetonitrile R1 to produce 1000 volumes.
| Time (Minutes) | Mobile phase A (% v/v) | Mobile phase B (% v/v) | Comment |
| 0-25 | 100 | 0 | isocratic |
| 25-55 | 100→0 | 0→100 | linear gradient |
| 55-70 | 0 | 100 | isocratic |
| 70-71 | 0→100 | 100→0 | linear gradient |
| 71-85 | 100 | 0 | re-equilibration |
When chromatograms are recorded under the prescribed conditions, the relative retentions with reference to ibuprofen (retention time about 26 minutes) are: impurity J, about 0.2; impurity N, about 0.3; impurity A, about 0.9; impurity B, about 1.08 and impurity E, about 1.11.SYSTEM
SUITABILITY
The test is not valid unless, in the chromatogram obtained with solution (3), the peak-to-valley ratio is at least 5.0, where Hp is the height above the baseline of the peak due to impurity B and Hv is the height above the baseline of the lowest point of the curve separating this peak from the peak due to ibuprofen.
LIMITS
Use the chromatogram supplied with ibuprofen for peak identification EPCRS and the chromatogram obtained with solution (5) to identify the peaks due to impurities A, J, and N. Use the chromatogram obtained with solution (4) to identify the peak due to impurity E.
In the chromatogram obtained with solution (1):
the area of any peak corresponding to impurity E is not greater than 3 times the area of the principal peak in the chromatogram obtained with solution (2) (0.3%);
the area of any peak corresponding to impurity A, J or N is not greater than 1.5 times the area of the principal peak in the chromatogram obtained with solution (2) (0.15% of each);
the area of any other secondary peak is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.1%);
the sum of the areas of any other secondary peaks is not greater than 7 times the area of the principal peak in the chromatogram obtained with solution (2) (0.7%).
Disregard any peak with an area less than 0.5 times the area of the principal peak in the chromatogram obtained with solution (2) (0.05%).
ASSAY
Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, using the following solutions.
(1) Shake a quantity of the powdered tablets containing 0.1 g of Ibuprofen in 50 mL of mobile phase, add sufficient mobile phase to product 100 mL and mix. Centrifuge and dilute 1 volume of the supernatant liquid to 10 volumes with the mobile phase.
(2) 0.01% w/v of ibuprofen BPCRS in the mobile phase.
CHROMATOGRAPHIC CONDITIONS
(a) Use a stainless steel column (25 cm × 4.6 mm) packed with octadecylsilyl silica gel for chromatography (10 μm) (Nucleosil C18 is suitable).
(b) Use isocratic elution and the mobile phase described below.
(c) Use a flow rate of 1.5 mL per minute.
(d) Use an ambient column temperature.
(e) Use a detection wavelength of 264 nm.
(f) Inject 20 μL of each solution.
MOBILE PHASE
3 volumes of orthophosphoric acid, 247 volumes of water and 750 volumes of methanol.
When the chromatograms are recorded under the prescribed conditions, the retention time of ibuprofen is about 7 minutes.
DETERMINATION OF CONTENT
Calculate the content of C13H18O2 in the tablets using the declared content of C13H18O2 in ibuprofen BPCRS.
IMPURITIES
The impurities limited by the requirements of this monograph include those listed under Ibuprofen.
